Nuclear Medicine And Biology SCIE

国际简称：NUCL MED BIOL 参考译名：核医学与生物学

主要研究方向：医学-核医学非预警期刊审稿周期：一般,3-8周约8周

《核医学与生物学》(Nuclear Medicine And Biology)是一本由Elsevier Inc.出版的以医学-核医学为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

4区中科院分区
Q1 JCR分区
38 年发文量
3.6 IF影响因子
未开放 是否OA
82 H-index
1993 创刊年份
Bimonthly 出版周期
Multi-Language 出版语言

Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.

These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.

Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.

[ 查看全部 ]

投稿咨询加急咨询

Nuclear Medicine And Biology期刊信息

ISSN：0969-8051
出版语言：Multi-Language
是否OA：未开放
E-ISSN：1872-9614
出版地区：UNITED STATES
是否预警：否
出版商：Elsevier Inc.
出版周期：Bimonthly
创刊时间：1993
开源占比：0.1881
Gold OA文章占比：35.59%
OA被引用占比：0.0953...
出版国人文章占比：0.1
出版撤稿占比：0
研究类文章占比：100.00%

Nuclear Medicine And Biology CiteScore评价数据（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指数

0.658

0.787

学科类别	分区	排名	百分位
大类：Medicine 小类：Radiology, Nuclear Medicine and Imaging	Q1	71 / 333	78%
大类：Medicine 小类：Cancer Research	Q2	107 / 230	53%
大类：Medicine 小类：Molecular Medicine	Q2	89 / 178	50%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Nuclear Medicine And Biology中科院评价数据

中科院 2023年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学	4区

中科院 2022年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学	4区

中科院 2021年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学	4区

中科院 2021年12月基础版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学	4区

中科院 2021年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学	4区

中科院 2020年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学	4区

Nuclear Medicine And Biology JCR评价数据（2023-2024年最新版）

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING	SCIE	Q1	36 / 204	82.6%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING	SCIE	Q2	53 / 204	74.26%

Nuclear Medicine And Biology历年数据统计

影响因子

中科院分区

Nuclear Medicine And Biology中国学者发文选摘

1、A radiopharmaceutical [89Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo
Author: Yu Tang, Yingjiang Hu, Weihao Liu, Lin Chen, Yan Zhao, Huan Ma, Jijun Yang, Yuanyou Yang, Jiali Liao, Jiming Cai, Yue Chen, Ning Liu

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2019, Vol.70, 23-31, DOI:10.1016/j.nucmedbio.2019.01.007
2、In vivo imaging characterization and anticancer efficacy of a novel HER2 affibody and pemetrexed conjugate in lung cancer model
Author: Honglei Jiao, Xinming Zhao, Jiahui Liu, Tuo Ma, Zhaoqi Zhang, Jingmian Zhang, Jianfang Wang

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2018, Vol., , DOI:10.1016/j.nucmedbio.2018.11.004
3、Radiosynthesis and biological evaluation of N-(2-[18F]fluoropropionyl)-3,4-dihydroxy-l-phenylalanine as a PET tracer for oncologic imaging
Author: Caihua Tang, Dahong Nie, Ganghua Tang, Siyuan Gao, Shaoyu Liu, Fuhua Wen, Xiaolan Tang

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.50, 39-46, DOI:10.1016/j.nucmedbio.2017.04.002
4、99mTc-3PRGD2 scintigraphy to stage liver fibrosis and evaluate reversal after fibrotic stimulus withdrawn
Author: Xin Zhang, Qiyong Guo, Yu Shi, Weina Xu, Shupeng Yu, Zhiguang Yang, Li Cao, Changping Liu, Zhoushe Zhao, Jun Xin

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.49, 44-49, DOI:10.1016/j.nucmedbio.2017.02.004
5、Simple and rapid radiosynthesis of N-18F-labeled glutamic acid as a hepatocellular carcinoma PET tracer
Author: Aixia Sun, Shaoyu Liu, Xiaolan Tang, Dahong Nie, Ganghua Tang, Zhanwen Zhang, Fuhua Wen, Xiaoyan Wang

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.49, 38-43, DOI:10.1016/j.nucmedbio.2017.02.003
6、Effect of methoxy group position on biological properties of 18F–labeled benzyl triphenylphosphonium cations
Author: Shuting Chen, Zuoquan Zhao, Ying Zhang, Wei Fang, Jie Lu, Xianzhong Zhang

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.49, 16-23, DOI:10.1016/j.nucmedbio.2017.02.002
7、Gefitinib enhances radiotherapeutic effects of 131I–hEGF targeted to EGFR by increasing tumor uptake of hEGF in tumor xenografts
Author: Lu Xia, He Peng, Luo Zhiqiang, Zhang Xiaoli

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.48, 63-68, DOI:10.1016/j.nucmedbio.2017.01.013
8、99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen
Author: Xiaoping Xu, Jianping Zhang, Silong Hu, Simin He, Xiao Bao, Guang Ma, Jianmin Luo, Jingyi Cheng, Yingjian Zhang

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.48, 69-75, DOI:10.1016/j.nucmedbio.2017.01.010